Bayer Pharmaceuticals Corporation (CT) And Onyx Pharmaceuticals, Inc. Release: Nexavar Receives Fast Track Designation From The FDA For Metastatic Liver Cancer

WEST HAVEN, Conn., and EMERYVILLE, Calif., June 13 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY - News) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) announced today that Nexavar® (sorafenib) tablets has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar was approved by the FDA in December 2005 for the treatment of patients with advanced renal cell carcinoma (RCC).